Luminex® 200™Multiplexing Instrument

This whitepaper explains how multiplex methods deep bisulfite sequencing and bisulfite PCR-Luminex can be used for DNA methylation analysis in research examining epigenetic modification.

Until recently, none of the commercially available multiplex molecular tests could provide the flexibility to satisfy clinicians' desire for both targeted and broad respiratory pathogen testing in a cost-effective manner for the lab and patient. The VERIEGENE® Respiratory Pathogens Flex Test (RP Flex) is the first commercial test that allows the user to choose any combination of 16 viral and bacterial targets for an individual sample at the time of test ordering, based on the clinician and patient’s needs. The purpose of this white paper is to deliver an overview of the advantages of using VERIEGENE® for your diagnostic needs.

Vaginitis results in >13 million physician office visits per year, and costs over $1 billion to the US healthcare system annually. However, up to 72% of women with vaginitis may remain undiagnosed or misdiagnosed. In this white paper, Luminex presents a summary of the condition and potential ways to effectively diagnose it in patients.

In this application note Luminex demonstrates how Luminex® xMAP® Technology can be used for cytokine analysis and was found to be more successful than flow cytometry. Luminex also compared a similar product from Thermo Fisher to show how the choice in equipment has to be based on the individual experiment.

Neurodegenerative disease processes involve a limited sample material (CSF) and an expanding number of biomarkers. This white paper highlights how reproducible and sensitive multiplexed assay systems, such as Luminex xMAP Technology, are ideal solutions for biomarker profiling in Alzheimer’s disease research. They can simultaneously interrogate multiple protein targets per sample, across a large number of samples, using small sample volumes.

This white paper assesses how multiplex assays can assist in the fight against Neglected Tropical Diseases (NTDs) through the presentation of a number of case studies. NTDs are a group of parasitic, bacterial, and viral infections affecting primarily the most impoverished and vulnerable populations in the world, and rank as the fourth-most devastating group of communicable diseases globally, behind only lower respiratory infections, HIV, and diarrheal diseases.

Many cancers have a higher probability of cure if detected early and treated properly. Early treatment requires early diagnosis, which can be enabled by screening of asymptomatic populations with high risk factors. This white paper discusses tests required for such screening that are sensitive and specific, as well as amenable to high throughput.

Epitope mapping is the process of identifying all of the antibody binding sites on a target protein. Epitope mapping facilitates drug design and patenting, and is therefore one of the key elements in drug development. It is also important for development of antibodies to be used in research or diagnostic assays, which minimizes cross-reactivity. This white paper discusses how epitope mapping can be improved by using Luminex® xMAP® multiplex assays instead of traditional ELISA technology.

Nearly half of the world’s population is at risk of a malaria infection, with over 247 million cases every year. The parasite, caused by various species of the Plasmodium parasite, kills approximately one million people annually, most of whom are small children. Over the past 40 years, there has been an upsurge in this “global killer” and controlling this disease presents major challenges to malaria researchers who need new solutions to properly monitor and control the disease.

As the causative agent of the acquired immune deficiency syndrome (AIDS) pandemic, HIV has been the focus of intense research for more than 30 years. In this white paper, learn how the reproducible, fast, sensitive, and highly-multiplexed assays for nucleic acid sequences, antigens, antibodies, and cytokine levels based on Luminex® xMAP® Technology provide optimal solutions for understanding HIV infection and development of a vaccine.

Associate Professor Jochen Schwenk discusses how bead-based affinity proteomics, using xMAP technology, is enabling researchers at the KTH Royal Institute of Technology, Stockholm, to map the entire human proteome.

IgA Nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. In this presentation, David Wimbury, a Ph.D. student at University of Leicester, UK, describes a Luminex-based multiplexing immunoassay to investigate the relationship between levels of serum biomarkers associated with B and T cell activation and the development of IgAN. His research highlights the importance of controlling for renal function in serum biomarkers when studying associations between biomarkers and IgAN.

In this presentation, Dr. Stéphane Azoulay, Associate Professor at Université Côte d'Azur, describes the development and application of a multiplex immunoassay to detect biomarkers for use in hazard assessment of aquatic systems.

Anti-cytokine autoantibodies are an emerging field, as their role is increasingly recognized in infectious diseases and inflammation and also as diagnostic tools in various syndromic presentations. In this presentation, Dr. Rainer Döffinger, Cambridge University Hospital, describes the development of a comprehensive panel to screen for serum anti-cytokine autoantibodies using Luminex xMAP technology.

In this presentation, Ramy Huber, MSc., research associate, ProteoMediX AG, describes how Luminex xMAP technology was used to develop a novel immunoassay for biomarkers associated with prostate cancer. Learn how the method has the potential to significantly lower the rate of unnecessary prostate biopsies which are negative for cancer by more than 50%. Learn about current issues surrounding prostate cancer diagnosis, Luminex assay development and clinical testing of the new assay.

A major cause of morbidity and mortality is streptococcus pneumoniae. In this video, Siân Faustini, Ph.D. student at the University of Birmingham, UK, presents her results on assessing immune responses to pneumococcal polysaccharide and conjugate vaccines in HIV. Faustini demonstrates differences in IgG subclass responses to vaccines by using a combination of multiplexed Luminex immunological assays.

The intensive use of antibiotics in animal husbandry and public health care has seen an increase in antimicrobial resistant strains of bacteria. In this video, Jeroen Peters, researcher at RIKILT Wageningen University, Netherlands, presents his findings on the detection of antibiotics using the Luminex multiplex screening technology xMAP®, further demonstrating its validation in raw milk analysis. The presented screening assay could support governmental inspection and may help to further reduce the use of antimicrobials in animal production.

Evelien Germeraad, MSc., researcher at the Wageningen Bioveterinary Research, Wageningen University & Research, Netherlands, describes a powerful method for the fast identification of avian influenza virus subtypes in poultry sera. Hear how the multiplex serological assay based on Luminex xMAP® technology enables the detection of haemagglutinin and neuraminidase surface protein subtypes simultaneously in one assay.

In this presentation, Finn Terje Hegge, chief technical officer of Genetic Analysis (GA), presents its standardized DNA probe-based assay for profiling the gut microbiota. He explains how Luminex xMAP® technology, in combination with the MagPlex® Microspheres, is well suited for the final steps of sorting and detection. Learn how GA is currently developing its clinically validated assay with this Luminex technology.

The excessive production of harmful autoantibodies is a hallmark of autoimmune disease. Recent research has also shown that autoantibody production is useful to characterize cancer patients. The characterization of patient sub groups is essential for the efficient development of therapies for both autoimmune disease and cancer. In this presentation, Hans-Dieter Zucht, Head of Technology, Protagen AG, describes the use of a Luminex-based assay to detect common reactivity patterns of human autoantibodies against endogenous protein targets, using clustered autoantibody reactivities.

We bring you insights, tips and knowledge from 11 experts as they tackle biomarker research using diverse methods

Discover SelectScience® video interviews and articles about the latest Alzheimer’s disease research methods

Discover the most exciting new developments in cell biology research this month

written by Luminex

written by Luminex

written by Luminex